Financial Data and Key Metrics Changes - Aytu BioScience reported a record net revenue of over $15.1 million for Q2 2021, representing a 377% increase compared to the same quarter last year and a 12% sequential growth over Q1 2021 [4][8] - The adjusted EBITDA loss was approximately $1.8 million, an improvement of over $1 million compared to the adjusted EBITDA loss of $2.9 million in Q2 2020 [8][11] - Gross profit for Q2 was $9.1 million, with a gross profit margin of approximately 60%, down from 81% in the same quarter last year due to lower margins from COVID-19 test kit sales [9][10] Business Line Data and Key Metrics Changes - The consumer health division achieved an all-time revenue high of $7.9 million, while the Rx division generated $7.2 million, a 25% increase from the previous quarter [6][14] - The pediatric segment, particularly Poly-Vi-Flor, contributed to Rx revenue growth, alongside revenue from COVID-19 test kits [15][19] Market Data and Key Metrics Changes - The COVID-19 testing market remains robust, with Aytu having successfully sourced an antigen test that has seen strong market acceptance [27][28] - The company anticipates continued demand for antibody testing as the market evolves [28] Company Strategy and Development Direction - Aytu is focused on integrating the Innovus Consumer Health business and the Cerecor pediatric assets, while also pursuing additional growth drivers and acquisitions [5][18] - The planned merger with Neos Therapeutics is expected to close by Q2 2021, creating a specialty pharmaceutical company with pro forma annual revenue exceeding $100 million [5][18] - The merger is anticipated to yield annual cost synergies of approximately $15 million starting in FY '22 [19] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's strategic transformation and the potential of the Healight technology in treating respiratory diseases [17][20] - The focus remains on top-line growth and achieving profitability, with a strong cash balance of over $62 million to support future initiatives [7][12] Other Important Information - Aytu completed a $28.75 million public offering, which will help pay down a substantial portion of Neos' debt upon merger closing [12] - The company ended the quarter with total assets of $167 million and equity of $113 million [12] Q&A Session Summary Question: Growth expectations for the pediatric side of the business - Management expects continued growth in the pediatric segment, leveraging experience from the Cerecor acquisition and the upcoming Neos transaction [22][24] Question: Contribution of COVID-19 business to overall revenues - The COVID-19 testing business has been meaningful, with management noting the importance of being opportunistic in this market while focusing on broader growth [25][27][28] Question: Future expectations for gross margins - Management indicated that gross margins are expected to stabilize between 70% to 80%, depending on the contributions from the Rx and consumer health segments [31][32]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: September 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-38247 AYTU BIOSCIENCE, INC. (www.aytubio.com) Delaware 47-0883144 (State or other jurisdiction of incorporation or organization) (IRS Emp ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 333-146542 AYTU BIOSCIENCE, INC. (Exact Name of Registrant as Specified in Its Charter) 47-0883144 | --- | --- | |---------------------------|------------------------------------ ...

Aytu BioScience, Inc. (NASDAQ:AYTU) Q3 2020 Results Earnings Conference Call May 14, 2020 4:30 PM ET Company Participants Joshua Disbrow - Chairman & CEO David Green - CFO Conference Call Participants Jeffrey Cohen - Ladenburg Thalmann Operator Good afternoon, and thank you for joining us at the Aytu BioScience Third Quarter Fiscal 2020 Business Update Call for the quarter ending March 31, 2020. With me this afternoon are Aytu's Chairman and Chief Executive Officer, Josh Disbrow; and Chief Financial Officer ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.0001 per share AYTU The NASDAQ Stock Market LLC FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: March 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission ...

Financial Performance - Revenues for the three months ended December 31, 2019 increased by 77% compared to the same period in 2018, with annual revenues increasing by 100% and 14% for the years ended June 30, 2019 and 2018, respectively [149]. - Product revenue for Q4 2019 was $3.2 million, a 77% increase from $1.8 million in Q4 2018, driven by the acquisition of the Pediatric Therapeutics portfolio [167]. - For the six months ended December 31, 2019, product revenue was $4.6 million, a 43% increase from $3.2 million in the same period of 2018 [166]. - The company reported a net loss of $214,247 in Q4 2019, significantly improved from a net loss of $4.7 million in Q4 2018, marking a 95% reduction [165]. - The gain from derecognition of contingent consideration was approximately $5.2 million in Q4 2019, contributing to the overall financial improvement [176]. Operating Expenses - Total operating expenses for Q4 2019 were $8.1 million, a 34% increase from $6.3 million in Q4 2018, with selling, general and administrative costs rising by 29.1% [165]. - Selling, general and administrative costs for the six months ended December 31, 2019, increased by 35.3% to $11.7 million from $8.6 million in the prior year [172]. - Research and development expenses decreased by 55.3% to $66,675 in Q4 2019 compared to $149,029 in Q4 2018, primarily due to reduced costs associated with the MiOXSYS System [170]. Cash Flow and Financing - Cash used in operations during the six months ended December 31, 2019 was $9.1 million, compared to $7.0 million for the same period in 2018, primarily due to the acquisition of the Pediatric Portfolio [149]. - Net cash used in operating activities for the six months ended December 31, 2019, was $9.1 million, higher than the net loss of $5.1 million due to derecognition of contingent consideration and increased accounts receivable [178]. - Net cash provided by financing activities in the six months ended December 31, 2019, was $9.3 million, primarily from an October 2019 offering [181]. Acquisitions and Mergers - The acquisition of the Pediatric Portfolio included a total consideration of $4.5 million in cash and approximately 9.8 million shares of Series G Convertible Preferred Stock, along with the assumption of up to $3.5 million in Medicaid rebates and product returns [157]. - The company expects to require capital beyond operating needs to complete and integrate the Pediatric Portfolio acquisition and the merger with Innovus Pharmaceuticals, Inc., which is expected to close on February 14, 2020 [149]. - The merger with Innovus Pharmaceuticals, Inc. is expected to involve the retirement of up to approximately 3.7 million shares of common stock and up to $16 million in milestone payments contingent on achieving certain revenue and profitability milestones [160]. - The company used $4.5 million for the acquisition of Cerecor during the six months ended December 31, 2019 [180]. Asset Position and Equity - The company has a current asset position of $74.5 million, which, along with expected receipts from ongoing product sales, will be used to fund operations [153]. - As of September 30, 2019, the company's stockholders' equity totaled approximately $2.3 million, but subsequent equity financing raised approximately $14.8 million, bringing the equity balance above the minimum Nasdaq requirement of $2.5 million [155]. Future Plans - The company plans to continue seeking to acquire additional commercial-stage or near-market products that offer distinct clinical advantages and patient benefits [148]. - The company has engaged a placement agent to refinance fixed obligations and is in discussions with lenders to establish a debt facility to provide capital [153].

Aytu BioScience, Inc. (NASDAQ:AYTU) Q2 2020 Earnings Conference Call February 13, 2020 4:30 PM ET Company Participants Josh Disbrow – Chairman and Chief Executive Officer Dave Green – Chief Financial Officer Conference Call Participants Carl Byrnes – Northland Securities Jeffrey Cohen – Ladenburg Thalmann Operator Good afternoon and thank you for joining us for the Aytu BioScience Second Quarter Fiscal 2020 Business Update Call for the Quarter Ended December 31, 2019. With me this afternoon are Aytu's Chair ...